Who bought inspiremd stock?
Company insiders that have bought InspireMD stock in the last two years include Gary S Roubin, Marvin Slosman, and Thomas J Kester. View insider buying and selling activity for InspireMD or or view top insider-buying stocks. How do I buy shares of InspireMD?
What is the upside from inspiremd's current price?
On average, they anticipate InspireMD's stock price to reach $10.50 in the next year. This suggests a possible upside of 132.8% from the stock's current price. View analysts' price targets for InspireMD or view top-rated stocks among Wall Street analysts. Who are InspireMD's key executives? Who are some of InspireMD's key competitors?
What is the new symbol for inspiremd?
Trading is expected to begin on June 8, 2021, under the symbols NSPRW and NSPRZ on the Nasdaq. About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.
How much money does inspiremd make a year?
InspireMD has a market capitalization of $35.70 million and generates $2.48 million in revenue each year. How many employees does InspireMD have? InspireMD employs 47 workers across the globe.
Will InspireMD stock go up?
Stock Price Forecast The 1 analysts offering 12-month price forecasts for InspireMD Inc have a median target of 5.25, with a high estimate of 5.25 and a low estimate of 5.25. The median estimate represents a +148.82% increase from the last price of 2.11.
Did Nspr reverse split?
InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR. WSB) recently announced a 1-for-15 reverse split of its common stock, effective as of yesterday.
What does InspireMD Inc do?
InspireMD is a commercial-stage medical device company with proprietary and innovative stent designs with integrated embolic prevention systems (EPS) delivering neurovascular protection and stroke prevention.
What happens to warrants after reverse split?
Accordingly, upon effectiveness of the reverse stock split, each outstanding warrant currently trading on the NYSE American under the symbol “NSPR.WS” shall become a warrant to purchase one thirty-fifth (1/35) of one share of common stock at an exercise price of $175.00 per full share of common stock, and each ...
What is Nspr stock?
Casper Sleep Inc (CSPR) 6.78 +0.48 (+7.62%) 01/24/22 [NYSE]
Where is InspireMD located?
When will InspireMD reverse split?
Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.
What is the NSPR symbol?
Shares of InspireMD reverse split on Tuesday, April 27th 2021. The 1-15 reverse split was announced on Wednesday, April 14th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 26th 2021. An investor that had 100 shares of InspireMD stock prior to the reverse split would have 7 shares after ...
What is the P/E ratio of InspireMD?
InspireMD trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NSPR."
Is Marketbeat better than InspireMD?
The P/E ratio of InspireMD is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Does InspireMD pay dividends?
What stocks does MarketBeat like better than InspireMD? Wall Street analysts have given InspireMD a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains.
What is InspireMD?
InspireMD does not currently pay a dividend.
Is InspireMD Inc stock A Buy?
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex coronary and vascular diseases. It offers MGuard and MGuard prime embolic protection stents for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions; and CGuard carotid embolic prevention systems for ... Read more
